Factor XI homodimer structure is essential for normal proteolytic activation by factor XIIa, thrombin, and factor XIa. 2008

Wenman Wu, and Dipali Sinha, and Sergei Shikov, and Calvin K Yip, and Thomas Walz, and Paul C Billings, and James D Lear, and Peter N Walsh
Sol Sherry Thrombosis Research Center, Temple University School of Medicine, Philadelphia, Pennsylvania 19140, USA.

Coagulation factor XI (FXI) is a covalent homodimer consisting of two identical subunits of 80 kDa linked by a disulfide bond formed by Cys-321 within the Apple 4 domain of each subunit. Because FXI(C321S) is a noncovalent dimer, residues within the interface between the two subunits must mediate its homodimeric structure. The crystal structure of FXI demonstrates formation of salt bridges between Lys-331 of one subunit and Glu-287 of the other subunit and hydrophobic interactions at the interface of the Apple 4 domains involving Ile-290, Leu-284, and Tyr-329. FXI(C321S), FXI(C321S,K331A), FXI(C321S,E287A), FXI(C321S,I290A), FXI(C321S,Y329A), FXI(C321S,L284A), FXI(C321S,K331R), and FXI(C321S,H343A) were expressed in HEK293 cells and characterized using size exclusion chromatography, analytical ultracentrifugation, electron microscopy, and functional assays. Whereas FXI(C321S) and FXI(C321S,H343A) existed in monomer/dimer equilibrium (K(d) approximately 40 nm), all other mutants were predominantly monomers with impaired dimer formation by analytical ultracentrifugation (K(d)=3-38 microm). When converted to the active enzyme, FXIa, all the monomeric mutants activated FIX similarly to wild-type dimeric FXIa. In contrast, these monomeric mutants could not be activated efficiently by FXIIa, thrombin, or autoactivation in the presence of dextran sulfate. We conclude that salt bridges formed between Lys-331 of one subunit and Glu-287 of the other together with hydrophobic interactions at the interface, involving residues Ile-290, Leu-284, and Tyr-329, are essential for homodimer formation. The dimeric structure of FXI is essential for normal proteolytic activation of FXI by FXIIa, thrombin, or FXIa either in solution or on an anionic surface but not for FIX activation by FXIa in solution.

UI MeSH Term Description Entries
D004220 Disulfides Chemical groups containing the covalent disulfide bonds -S-S-. The sulfur atoms can be bound to inorganic or organic moieties. Disulfide
D005172 Factor XI Stable blood coagulation factor involved in the intrinsic pathway. The activated form XIa activates factor IX to IXa. Deficiency of factor XI is often called hemophilia C. Coagulation Factor XI,Plasma Thromboplastin Antecedent,Blood Coagulation Factor XI,Factor 11,Factor Eleven,Antecedent, Plasma Thromboplastin,Factor XI, Coagulation,Thromboplastin Antecedent, Plasma
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013917 Thrombin An enzyme formed from PROTHROMBIN that converts FIBRINOGEN to FIBRIN. Thrombase,Thrombin JMI,Thrombin-JMI,Thrombinar,Thrombostat,alpha-Thrombin,beta,gamma-Thrombin,beta-Thrombin,gamma-Thrombin,JMI, Thrombin
D015945 Factor XIa Activated form of factor XI. In the intrinsic pathway, Factor XI is activated to XIa by factor XIIa in the presence of cofactor HMWK; (HIGH MOLECULAR WEIGHT KININOGEN). Factor XIa then activates factor IX to factor IXa in the presence of calcium. Coagulation Factor XIa,Factor XI, Activated,Activated Factor XI,Blood Coagulation Factor XI, Activated,Contact Activation Product,Factor 11A,Factor Eleven A,Factor XIa, Coagulation
D015956 Factor XIIa Activated form of factor XII. In the initial event in the intrinsic pathway of blood coagulation, kallikrein (with cofactor HIGH MOLECULAR WEIGHT KININOGEN) cleaves factor XII to XIIa. Factor XIIa is then further cleaved by kallikrein, plasmin, and trypsin to yield smaller factor XII fragments (Hageman-Factor fragments). These fragments increase the activity of prekallikrein to kallikrein but decrease the procoagulant activity of factor XII. Coagulation Factor XIIa,Factor XII, Activated,Activated Factor XII,Blood Coagulation Factor XII, Activated,Factor 12A,Factor Twelve A,Hageman-Factor Fragments,Prekallikrein Activator,Activator, Prekallikrein,Factor XIIa, Coagulation,Fragments, Hageman-Factor,Hageman Factor Fragments
D017434 Protein Structure, Tertiary The level of protein structure in which combinations of secondary protein structures (ALPHA HELICES; BETA SHEETS; loop regions, and AMINO ACID MOTIFS) pack together to form folded shapes. Disulfide bridges between cysteines in two different parts of the polypeptide chain along with other interactions between the chains play a role in the formation and stabilization of tertiary structure. Tertiary Protein Structure,Protein Structures, Tertiary,Tertiary Protein Structures
D057927 Hydrophobic and Hydrophilic Interactions The thermodynamic interaction between a substance and WATER. Hydrophilic Interactions,Hydrophilic and Hydrophobic Interactions,Hydrophilicity,Hydrophobic Interactions,Hydrophobicity,Hydrophilic Interaction,Hydrophilicities,Hydrophobic Interaction,Hydrophobicities,Interaction, Hydrophilic,Interaction, Hydrophobic,Interactions, Hydrophilic,Interactions, Hydrophobic
D018360 Crystallography, X-Ray The study of crystal structure using X-RAY DIFFRACTION techniques. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) X-Ray Crystallography,Crystallography, X Ray,Crystallography, Xray,X Ray Crystallography,Xray Crystallography,Crystallographies, X Ray,X Ray Crystallographies
D019281 Dimerization The process by which two molecules of the same chemical composition form a condensation product or polymer. Dimerizations

Related Publications

Wenman Wu, and Dipali Sinha, and Sergei Shikov, and Calvin K Yip, and Thomas Walz, and Paul C Billings, and James D Lear, and Peter N Walsh
January 1993, Seminars in thrombosis and hemostasis,
Wenman Wu, and Dipali Sinha, and Sergei Shikov, and Calvin K Yip, and Thomas Walz, and Paul C Billings, and James D Lear, and Peter N Walsh
September 2007, The Journal of biological chemistry,
Wenman Wu, and Dipali Sinha, and Sergei Shikov, and Calvin K Yip, and Thomas Walz, and Paul C Billings, and James D Lear, and Peter N Walsh
July 2000, The Journal of biological chemistry,
Wenman Wu, and Dipali Sinha, and Sergei Shikov, and Calvin K Yip, and Thomas Walz, and Paul C Billings, and James D Lear, and Peter N Walsh
April 1991, The Journal of biological chemistry,
Wenman Wu, and Dipali Sinha, and Sergei Shikov, and Calvin K Yip, and Thomas Walz, and Paul C Billings, and James D Lear, and Peter N Walsh
April 1980, Biochemistry,
Wenman Wu, and Dipali Sinha, and Sergei Shikov, and Calvin K Yip, and Thomas Walz, and Paul C Billings, and James D Lear, and Peter N Walsh
December 2011, Blood,
Wenman Wu, and Dipali Sinha, and Sergei Shikov, and Calvin K Yip, and Thomas Walz, and Paul C Billings, and James D Lear, and Peter N Walsh
December 1977, Biochemistry,
Wenman Wu, and Dipali Sinha, and Sergei Shikov, and Calvin K Yip, and Thomas Walz, and Paul C Billings, and James D Lear, and Peter N Walsh
October 1999, Thrombosis and haemostasis,
Wenman Wu, and Dipali Sinha, and Sergei Shikov, and Calvin K Yip, and Thomas Walz, and Paul C Billings, and James D Lear, and Peter N Walsh
December 1986, The Journal of clinical investigation,
Wenman Wu, and Dipali Sinha, and Sergei Shikov, and Calvin K Yip, and Thomas Walz, and Paul C Billings, and James D Lear, and Peter N Walsh
April 2019, Arteriosclerosis, thrombosis, and vascular biology,
Copied contents to your clipboard!